Table of Contents List of Tables List of Figures Introduction Global Markets Direct Report Coverage Inclusion Body Myositis (IBM) - Overview Inclusion Body Myositis (IBM) - Therapeutics Development Pipeline Overview Pipeline by Companies Pipeline by Universities/Institutes Products under Development by Companies Products under Development by Universities/Institutes Inclusion Body Myositis (IBM) - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Inclusion Body Myositis (IBM) - Companies Involved in Therapeutics Development Acceleron Pharma Inc KPI Therapeutics Inc Milo Biotechnology LLC Nobelpharma Co Ltd Orphazyme ApS Ultragenyx Pharmaceutical Inc Inclusion Body Myositis (IBM) - Drug Profiles AAV1-Follistatin - Drug Profile Product Description Mechanism Of Action R&D Progress ACE-083 - Drug Profile Product Description Mechanism Of Action R&D Progress aceneuramic acid ER - Drug Profile Product Description Mechanism Of Action R&D Progress ALZ-1903 - Drug Profile Product Description Mechanism Of Action R&D Progress ALZ-801 - Drug Profile Product Description Mechanism Of Action R&D Progress arimoclomol - Drug Profile Product Description Mechanism Of Action R&D Progress dalazatide - Drug Profile Product Description Mechanism Of Action R&D Progress DEXM-74 - Drug Profile Product Description Mechanism Of Action R&D Progress Gene Therapy to Activate GNE for Hereditary Inclusion Body Myopathy - Drug Profile Product Description Mechanism Of Action R&D Progress UX-001P - Drug Profile Product Description Mechanism Of Action R&D Progress UX-007 - Drug Profile Product Description Mechanism Of Action R&D Progress Inclusion Body Myositis (IBM) - Dormant Projects Inclusion Body Myositis (IBM) - Discontinued Products Inclusion Body Myositis (IBM) - Product Development Milestones Featured News & Press Releases Dec 15, 2011: New Zealand Pharma Obtains FDA Orphan Drug Designation For DEX-M74 To Treat Hereditary Inclusion Body Myopathy Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer

List of Tables Number of Products under Development for Inclusion Body Myositis (IBM), H2 2017 Number of Products under Development by Companies, H2 2017 Number of Products under Development by Universities/Institutes, H2 2017 Products under Development by Companies, H2 2017 Products under Development by Universities/Institutes, H2 2017 Number of Products by Stage and Target, H2 2017 Number of Products by Stage and Mechanism of Action, H2 2017 Number of Products by Stage and Route of Administration, H2 2017 Number of Products by Stage and Molecule Type, H2 2017 Inclusion Body Myositis (IBM) - Pipeline by Acceleron Pharma Inc, H2 2017 Inclusion Body Myositis (IBM) - Pipeline by KPI Therapeutics Inc, H2 2017 Inclusion Body Myositis (IBM) - Pipeline by Milo Biotechnology LLC, H2 2017 Inclusion Body Myositis (IBM) - Pipeline by Nobelpharma Co Ltd, H2 2017 Inclusion Body Myositis (IBM) - Pipeline by Orphazyme ApS, H2 2017 Inclusion Body Myositis (IBM) - Pipeline by Ultragenyx Pharmaceutical Inc, H2 2017 Inclusion Body Myositis (IBM) - Dormant Projects, H2 2017 Inclusion Body Myositis (IBM) - Discontinued Products, H2 2017 List of Figures Number of Products under Development for Inclusion Body Myositis (IBM), H2 2017 Number of Products under Development by Companies, H2 2017 Number of Products by Targets, H2 2017 Number of Products by Stage and Targets, H2 2017 Number of Products by Mechanism of Actions, H2 2017 Number of Products by Stage and Mechanism of Actions, H2 2017 Number of Products by Routes of Administration, H2 2017 Number of Products by Stage and Routes of Administration, H2 2017 Number of Products by Molecule Types, H2 2017 Number of Products by Stage and Molecule Types, H2 2017

Acceleron Pharma Inc KPI Therapeutics Inc Milo Biotechnology LLC Nobelpharma Co Ltd Orphazyme ApS Ultragenyx Pharmaceutical Inc